drugset / Trial / NCT03292133
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: * EGF816 * Gefitinib
Timeline
- Start
- 2017-10-31
- Primary completion
- 2021-12-31
- Completion
- 2025-03-04
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |
| Subject | Nazartinib | Small molecule | — | Oral |